Blog

Goldman Sachs expects a strong, innovation‑driven M&amp;A cycle into 2026, with healthcare one of the core beneficiaries of abundant capital, AI adoption and a more constructive regulatory backdrop. While the firm does not publish a standalone “healthcare‑only 2026 M&amp;A outlook” publicly, its global M&amp;A and equity views, combined with external synthesis of their comments, point to higher healthcare deal volumes and a rising share of large, transformative transactions.Big picture: Goldman’s 2026 M&amp;A stanceGoldman frames 2026 M&amp;A as a “think big, build bigger” phase, driven by strategic repositioning and scale, powered by AI and ample public/private capital.Management has publicly described the outlook for M&amp;A into 2026 as “very encouraging,” expecting current momentum to continue rather than fade.External analysis that leans on Goldman’s numbers suggests global M&amp;A volumes could approach or exceed the prior 2021 record, with a particular pickup in mega‑deals (above 5 billion dollars).Healthcare’s role in that thesisRecent materials reference healthcare as one of the sectors leading risk‑asset performance into 2026, supported by resilient earnings and structural demand.Sector commentary across banks (and echoed in independent write‑ups of Goldman’s outlook) highlights healthcare as a prime user of AI, data platforms and automation, which in turn pulls in both strategic and financial buyers via M&amp;A.Healthcare is repeatedly cited among the top beneficiaries of improved financing conditions and more deal‑friendly antitrust stances, enabling larger, more complex combinations.HealthTech / MedTech‑specific implicationsExternal healthcare M&amp;A forecasts that reference Goldman’s global deal value expectations project accelerating HealthTech and MedTech consolidation in 2026, with deal flow shifting from numerous small transactions to fewer, higher‑value platform deals.Hotspots flagged in these syntheses include AI‑enabled revenue cycle and workflow platforms, advanced diagnostics and data/AI infrastructure, neurovascular and other high‑growth therapeutic areas, and clinically validated digital therapeutics with clear reimbursement pathways.Large strategics and PE are expected to use M&amp;A to acquire AI and GenAI capabilities rather than build them, especially to protect margins and address patent cliffs or pricing pressure. Deal structure, scale and financing The 2026 setup assumes stabilising or easier credit markets, which lower the cost of leveraged buyouts and corporates’ ability to fund larger all‑cash or cash‑plus‑stock deals. With CEO confidence recovering and equity markets still constructive (though with slower expected returns than 2025), stock‑for‑stock and mixed consideration deals become more attractive, particularly for sizeable healthcare transactions. Forecasts call for modest growth in US deal volumes by count but disproportionately higher growth in aggregate value, reflecting a greater share of large and mega‑deals rather than a pure volume reboundSource: <a href="https://www.goldmansachs.com/what-we-do/investment-banking/insights/articles/2026-ma-outlook">https://www.goldmansachs.com/what-we-do/investment-banking/insights/articles/2026-ma-outlook</a>

Goldman Sachs - Healthcare M&A forecasts and predictions 2026

Morgan Stanley’s 2026 outlook identifies Healthcare as one of its top overweight sectors, projecting a significant "revival" after years of relative underperformance. This optimism is driven by a transition from a defensive, inflation-hedging posture to a growth-oriented "late-cycle" phase characterised by rate cuts, fiscal stimulus and a broadening of corporate earnings.For MedTech, the narrative for 2026 is centered on a "clearing event", where the market moves past post-pandemic inventory destocking and supply chain shocks toward a more "benign operating environment."Key Investment Themes for 2026Morgan Stanley’s strategists, including Chief Global Cross-Asset Strategist Serena Tang, highlight several pillars for the healthcare recovery:1. The "K-Shaped" Recovery &amp; M&amp;A ResurgenceThe sector is seeing a sharp bifurcation. Quality assets, those with durable growth and high return on invested capital (ROIC), are expected to command premium valuations.M&amp;A Uptrend: After reaching a three-decade low relative to GDP, M&amp;A activity is firmly in an uptrend. Morgan Stanley anticipates that 2026 will see medtech companies deploying capital with "greater precision," using divestitures of non-core assets to fund acquisitions in high-growth procedural segments like cardiovascular and neurostimulation.Private Equity Influence: PE-backed firms are moving away from "growth-at-all-costs" toward profitable scalability, often acting as the primary engine for deal volume in the mid-market. 2. AI as an Efficiency Enabler (Not Just Hype) Morgan Stanley views 2026 as the year AI moves from speculative "agentic" promises to measurable operational impact.Commercial Applications: AI is being integrated into robotic-assisted surgery, predictive monitoring, and diagnostic imaging to improve patient outcomes and system resilience. Workflow Integration: "Tech-enabled" medtech businesses that can reduce clinician burnout and fit into existing hospital workflows (using standards like FHIR and DICOM) are prioritised. 3. Structural Shifts: Lower-Acuity &amp; Home Care A major theme is the migration of care away from expensive hospital settings.At-Home Diagnostics: Growth is expected in wearable cardioverter defibrillators (WCDs) and at-home monitoring devices. The "Plug-and-Play" Hospital: Investment is flowing into modular clinical spaces that allow for rapid deployment of new devices and robotics without major infrastructure rebuilds. 4. Regulatory &amp; Policy "Clearing" While 2025 was marked by uncertainty regarding drug pricing and tariffs, 2026 is viewed as a year where the market gains clarity.Inflation Reduction Act (IRA): 2026 marks the first year of negotiated prices for key Medicare drugs, which Morgan Stanley notes will create a tailwind for TechBio platforms that promise to reduce the time and cost of R&amp;D. Innovation Surge: A reopening IPO window is expected specifically for diagnostics and minimally invasive technology companies that have clear commercial traction. &nbsp; Comparison of 2026 Healthcare Sub-Sectors MedTech &gt; BullishBioPharma &gt; SelectiveHealth IT &gt; High GrowthLife Sciences &gt; RecoverySource: <a href="https://www.youtube.com/watch?v=uHPoQXAmmEw">https://www.youtube.com/watch?v=uHPoQXAmmEw</a>

Morgan Stanley Investment Themes 2026: Healthcare revival and Bullish on MedTech

The European healthcare technology and services landscape is entering 2026 at a profound inflection point. After a period of post-pandemic recalibration in 2024 and a tentative recovery in 2025, the market is poised for a robust, albeit structurally transformed, resurgence in mergers and acquisitions (M&amp;A). The defining theme for 2026 is "Industrialisation." &nbsp;&nbsp; This concept signifies a departure from the fragmented, venture subsidised experimentation that characterised the 2019–2022 era, moving instead toward scalable, profit generating platforms that leverage operational leverage, regulatory fortitude and vertical integration to dominate their respective sub-sectors. &nbsp;&nbsp; The consolidation wave of 2026 will not be a rising tide that lifts all boats. Instead, it will be defined by a stark bifurcation in asset desirability and deal rationale. On one side of the ledger, "Analog" healthcare services, encompassing veterinary, dental, ophthalmology and fertility clinics will witness continued intensified "buy-and-build" activity. This is driven principally by private equity (PE) sponsors seeking to arbitrage highly fragmented markets, particularly in Southern and Eastern Europe, where entry multiples remain attractive relative to the saturated markets of the UK and the Nordics. On the other side, "Digital" and high-technology segments, including AI-enabled radiology, digital pathology and tech-enabled home care, will experience strategic consolidation. &nbsp;&nbsp; Here, hardware incumbents and large-cap technology firms will acquire software innovators not merely for growth, but to secure data sovereignty and "compliance moats" in the face of an increasingly rigorous EU regulatory architecture. &nbsp;&nbsp; Three primary catalysts will underpin the deal flow in 2026, creating a unique pressure cooker for M&amp;A activity: &nbsp;&nbsp; First, Regulatory Darwinism will force a clearing event. The full implementation of the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) has created a capital-intensive barrier to entry that is largely untenable for stand-alone Small and Medium-sized Enterprises (SMEs). The costs associated with Notified Body certification and clinical data generation act as a guillotine for undercapitalized firms, driving them into the arms of larger strategics who possess the necessary regulatory infrastructure. Simultaneously, the new EU AI Act and Digital Omnibus introduce complex compliance requirements for high-risk AI systems, effectively barring new entrants who lack the resources for robust data governance and post-market surveillance. &nbsp;&nbsp; Second, the Private Equity Liquidity Cycle is reaching a critical maturity. With approximately $2.5 Trillion in global dry powder and a significant backlog of assets from the 2019–2021 vintage requiring exit, PE firms are under immense pressure to return capital to Limited Partners (LPs). However, with the IPO market remaining selective and focused only on assets with proven profitability and scale, sponsors will increasingly utilise continuation funds and secondary buyouts to drive consolidation. This allows them to hold high performing assets for longer, financing further add-on acquisitions to build pan-European champions before an eventual exit. &nbsp;&nbsp; Third, the Structural Shift to Outpatient and Home Settings is reallocating capital. Health systems across Europe, burdened by aging populations and workforce shortages, are aggressively pushing care out of high cost hospital settings. This is fuelling a massive capital rotation toward technologies and services that facilitate "hospital-at-home" models, remote monitoring and decentralised diagnostics. &nbsp; M&amp;A in 2026 will heavily favour assets that enable this transition, such as tech-enabled home care providers and outpatient surgery centres, which offer an immediate release valve for strained public health budgets. &nbsp;&nbsp; This report provides an analysis of these dynamics, dissecting the market into key verticals of consolidation, financial mechanisms, and regional hotspots to offer a comprehensive outlook for 2026.Source: <a href="https://www.healthcare.digital/single-post/which-sub-sectors-of-european-healthtech-and-medtech-are-most-likely-to-see-consolidation-in-2026">https://www.healthcare.digital/single-post/which-sub-sectors-of-european-healthtech-and-medtech-are-most-likely-to-see-consolidation-in-2026</a>To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

European HealthTech and MedTech Consolidation Outlook 2026: The Great Rationalisation and the Industrialisation of Care

Nelson Advisors emerging European HealthTech M&amp;A reference point going into 2026Nelson Advisors is increasingly referred to as a European HealthTech and MedTech M&amp;A reference point going into 2026, combining deep sector specialism with visible thought leadership and a forward‑leaning market outlook.​Why is Nelson Advisors seen as a key reference pointIndependent analyses describe Nelson Advisors as one of Europe’s leading healthcare technology M&amp;A boutiques, exclusively focused on Digital Health, HealthTech, Health IT, consumer health, cybersecurity and Healthcare AI across the UK, Europe and North America.​ Articles emphasise that its “leading” status is sector‑specific: the firm is not a volume leader across all M&amp;A, but a specialist benchmark within HealthTech, where nuanced understanding of regulation, data and AI is critical.​ 2025 work that sets up 2026 The 2025 year‑in‑review highlights Nelson Advisors’ role across founder‑led exits, distressed and consolidation deals, roll‑up strategies and complex cross‑border financings, positioning the firm as a central architect of recent European HealthTech dealflow.​The firm introduced frameworks such as the “Integrated HealthTech Fit Model” and produced detailed analyses of valuation multiples and M&amp;A drivers, which have been cited in wider healthcare M&amp;A commentary and Deloitte updates.​2026 outlook and strategic thesesNelson Advisors’ 2025 year‑in‑review and 2026 prediction pieces forecast a pivot from the fragmented, lower‑value deal environment of 2024–2025 toward fewer, high‑value, transformative and “mega‑deal” transactions as credit conditions ease.​The firm expects Big Tech and major pharma to accelerate acquisitions of interoperable, AI‑enabled HealthTech platforms, aligning with trends such as CMS FHIR API 2026 mandates and continued “digital left shift” of care to home and community settings.​ Specialisms that matter for 2026 Nelson Advisors places explicit focus on sub‑sectors expected to drive 2026 value: Healthcare AI, interoperability infrastructure, cybersecurity, Health IT roll‑ups, and “String of Pearls” biopharma/MedTech strategies.​ The boutique is one of the few to call out Seed/Series A HealthTech M&amp;A “off‑ramps,” distressed asset arbitrage and regulatory‑driven consolidation as core service lines, giving it a differentiated lens on upcoming European HealthTech restructuring.​ Thought leadership footprint Since 2023, Nelson Advisors has produced a sustained stream of HealthTech and MedTech thought‑leadership content (valuation drivers, 2026 market predictions, UK HealthTech &amp; MedTech 2026 outlook, cap‑table issues, etc.), making its publications a recurring reference for founders, investors and strategics.​This combination of deal execution, proprietary frameworks, and widely shared insight underpins why commentators increasingly treat Nelson Advisors as a reference point for European HealthTech M&amp;A strategy heading into 2026.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk" data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk﻿</a>

Nelson Advisors emerges as a Key European HealthTech and MedTech M&A reference point going into 2026

AI-focused health tech deals now account for roughly three-quarters of overall health tech funding and the new J.P. Morgan sector report explicitly frames AI as the dominant theme in HealthTech investing for 2025. This dominance is most visible in data‑rich, workflow‑embedded applications that target administrative efficiency and clinical productivity rather than “pure” clinical AI alone.​What the JPM report actually saysJ.P. Morgan’s 2025 “Sector Spotlight: Healthcare Technology” notes that AI and automation are central to nearly every major HealthTech trend, from patient access to back‑office operations.​ The report highlights that AI‑enabled offerings are increasingly standard among new HealthTech startups and that companies “building with AI” trade at a valuation premium to non‑AI peers.​ Funding share: AI now dominates A companion analysis of deal flow finds that around 75% of HealthTech and tech‑enabled healthcare services deals funded in 2025 were AI‑focused, i.e., explicitly built around AI or heavy automation.​ Within venture, Series B has become the main locus of AI HealthTech capital (over 60% of AI‑focused rounds), signalling investor willingness to back large “TAM‑disrupting” AI plays earlier in the scaling curve.​ Where AI capital is concentrating JPM’s material and related commentary flag two priority use‑case clusters: administrative efficiency (billing, coding, documentation, prior auth) and clinical productivity (decision support, triage, imaging, predictive analytics).​ Ambient AI for transcription/documentation and hospital/IDN analytics platforms are repeatedly cited as attracting several large venture rounds in 2025, alongside AI‑heavy virtual care and RCM tools.​ Implications for non‑AI HealthTech Commentary around the report notes that this capital concentration risks marginalising non‑AI health tech ventures, which may face increasing difficulty raising unless they can clearly articulate data/AI leverage or defensible niches.​ At the same time, J.P. Morgan’s broader healthcare pieces stress that AI is now viewed as an enabling layer across the sector rather than a standalone vertical, suggesting many “non‑AI” plays will need to embed AI capabilities to remain attractive.​ Takeaways for an investor / advisor lens Expect continued valuation premiums for AI‑native, data‑rich platforms with clear workflow integration and ROI, especially around admin automation, clinical ops, and enterprise analytics.​ Non‑AI HealthTech assets will increasingly be diligenced on their data assets, integration points and AI‑readiness, even if their current product is not marketed as AI.Source: <a href="https://www.jpmorgan.com/insights/banking/commercial-banking/how-ai-m-and-a-and-policy-planning-are-shaping-health-care">https://www.jpmorgan.com/insights/banking/commercial-banking/how-ai-m-and-a-and-policy-planning-are-shaping-health-care</a>

JP Morgan Investment Report: AI Now Dominates Health Tech Investment

JPM 2026 is expected to double‑down on AI, capital discipline, and late‑stage “de‑risked” assets, with oncology, neuro and AI‑enabled platforms at the center of the narrative.​1. AI everywhere, but judged on ROI Conference materials and satellite briefings flag AI‑driven R&amp;D, diagnostics, and operationsas a defining theme, not a side track.​ VCs expect 2026 funding to favor AI that clearly cuts cost, boosts productivity, or enables new economics (e.g. payor‑facing analytics, revenue‑cycle and admin AI, ambient documentation) rather than generic “AI for X” point tools.​ 2. Therapeutic focus: oncology, neuro, hematology JPM 2026 agendas and attendee guides emphasize oncology, neuropsychiatry/neurology, and hematology as the leading therapeutic spotlight areas.​ Expect significant attention to late‑stage and commercial‑stage assets in complex cancers, schizophrenia/bipolar, neurodegeneration, and rare hematologic diseases, often paired with biomarker and companion diagnostic plays.​ 3. Biotech and “TechBio” reset, not rebound Preview pieces suggest a continued bifurcation: high‑quality, data‑rich “TechBio” platforms and validated assets re‑rate, while sub‑scale discovery stories struggle to raise on acceptable terms.​ Gene/cell therapy, precision oncology, and platform biotechs will be framed around capital efficiency, partnering, and risk‑sharing structures rather than pure “moonshot” narratives.​ 4. Digital health, medtech and IPO/M&amp;A dynamics Digital health and medtech sessions are expected to focus on:Profitability and unit‑economic proof for care‑delivery and virtual models. Device‑plus‑software and wearable / monitoring platforms with real‑world data moats.​2026 is widely framed as a “clearing event” year: a thin IPO window with a handful of scaled, profitable issuers, alongside more take‑privates, roll‑ups and strategic acquisitions, especially in AI and tech‑enabled services.​ 5. Policy, regulation and trust in AI Agendas and commentary highlight regulatory and policy panels around FDA modernization, AI/ML frameworks, privacy, and global market access as core content rather than side events.​ Expect heavy discussion of algorithmic bias, safety, explainability, and reimbursement for AI‑enabled products, as payors and regulators push for demonstrable clinical and economic value.​ 6. Health system strategy and care models Post‑2025 takeaways indicate providers coming into JPM 2026 focused on:Shifting volume to outpatient, home‑based and lower‑cost settings. Using AI, automation and new contracting models to manage labor, margin pressure and chronic care at scale.​ Partnerships between big tech, payors, and IDNs around data, AI and “care‑anywhere” models are expected to be key deal and JV storylines during the week.<a data-mce-href="https://www.jpmorgan.com/about-us/events-conferences/health-care-conference" href="https://www.jpmorgan.com/about-us/events-conferences/health-care-conference" title="https://www.jpmorgan.com/about-us/events-conferences/health-care-conference" target="_blank" rel="noopener" data-mce-selected="inline-boundary">https://www.jpmorgan.com/about-us/events-conferences/health-care-conference</a>

Nelson Advisors

Blog

Goldman Sachs - Healthcare M&A forecasts and predictions ...

Morgan Stanley Investment Themes 2026: Healthcare revival...

European HealthTech and MedTech Consolidation Outlook 202...

Nelson Advisors emerges as a Key European HealthTech and ...

JP Morgan Investment Report: AI Now Dominates Health Tech...

J.P. Morgan Annual Healthcare Conference 2026: Key predic...